| Name | Title | Contact Details |
|---|---|---|
Brian James |
CFO / VP of Finance and Accounting | Profile |
Since its beginning in 2007 as a technical staffing and business solutions group in Annapolis, Md., Syndicus has evolved into a highly respected technical staffing and consulting solutions group that provides talent and solutions for three focus areas: Health Information Technology, Life Sciences Solutions and Technology Services. We pride ourselves in partnering with top subject matter experts who ensure candidates, consultants and solutions meet clients' specialized needs. In 2012, Syndicus achieved both a full national accreditation with the Management Services Organization Accreditation Program (MSOAP) from the Electronic Healthcare Network Accreditation Commission (EHNAC) and the MSO State Designation from the Maryland Health Care Commission (MHCC). The two certifications enable Syndicus and its electronic health records (EHR) hosted solutions provider eCast Corporation to continue working with Maryland healthcare providers on EHR adoption efforts – and subsequent achievement of Meaningful Use.
Newcastle Place is a Mequon, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We re committed to breakthrough firsts in womens sexual health. Novel ideas fuel our entrepreneurial passion. At Sprout, we celebrate ownership, boldness, quirkiness, learning, family and appreciation. They are central to what we stand for and what we re trying to collectively accomplish.
Sunset Manor Inc is a Irene, SD-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
lcelyx was founded in 2010 with venture capital backing based on Gut Sensory Modulation (GSM) technology. Elcelyx`s proprietary, first-in-class Gut Sensory Modulators are delivered directly to the lower gut where they act on molecular targets to elicit physiological and pharmacological effects. The Elcelyx proprietary product candidate, NewMet for Type 2 diabetes is entering Phase 2b development and is a blockbuster opportunity designed to address the unmet needs in the oral anti-diabetic market. Elcelyx is led by an experienced management team and Board of Directors with track records of success in drug development and commercialization. Premier investors along with seasoned scientists and clinicians support the team. In September 2013, Elcelyx announced the formation of NaZura BioHealth Inc, a separate company established to focus on the development on non-NewMet assets.